Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Shock, Cardiogenic D012770 5 associated lipids
Shock D012769 11 associated lipids
Seizures D012640 87 associated lipids
Scleroderma, Systemic D012595 16 associated lipids
Osteosarcoma D012516 50 associated lipids
Salmonella Infections, Animal D012481 9 associated lipids
Rhinitis D012220 10 associated lipids
Rheumatic Diseases D012216 7 associated lipids
Respiratory Hypersensitivity D012130 18 associated lipids
Respiratory Distress Syndrome, Adult D012128 15 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Pulmonary Fibrosis D011658 24 associated lipids
Pulmonary Edema D011654 23 associated lipids
Psoriasis D011565 47 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Proteinuria D011507 30 associated lipids
Pregnancy Complications, Hematologic D011250 11 associated lipids
Pregnancy Complications, Cardiovascular D011249 11 associated lipids
Polycythemia Vera D011087 13 associated lipids
Pneumonia, Pneumococcal D011018 3 associated lipids
Pneumococcal Infections D011008 7 associated lipids
Pleurisy D010998 20 associated lipids
Platelet Storage Pool Deficiency D010981 3 associated lipids
Peritonitis D010538 38 associated lipids
Aggressive Periodontitis D010520 8 associated lipids
Parkinson Disease D010300 53 associated lipids
Pancreatitis D010195 10 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Pain D010146 64 associated lipids
Osteonecrosis D010020 5 associated lipids
Neutropenia D009503 15 associated lipids
Neurologic Manifestations D009461 1 associated lipids
Neuroblastoma D009447 66 associated lipids
Neuralgia D009437 28 associated lipids
Nervous System Diseases D009422 37 associated lipids
Nerve Degeneration D009410 53 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Neoplasms, Germ Cell and Embryonal D009373 4 associated lipids
Neoplastic Cells, Circulating D009360 5 associated lipids
Nasal Polyps D009298 26 associated lipids
Multiple Trauma D009104 2 associated lipids
Multiple Sclerosis D009103 13 associated lipids
Mouth, Edentulous D009066 1 associated lipids
Migraine Disorders D008881 11 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Meningioma D008579 11 associated lipids
Memory Disorders D008569 33 associated lipids
Melanoma D008545 69 associated lipids
Medulloblastoma D008527 22 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Kelly GL and Eiseman B Development of a new vascular prosthetic: lessons learned. 1982 Arch Surg pmid:7125901
Sugiura T et al. Ether phospholipids in guinea pig polymorphonuclear leukocytes and macrophages. Occurrence of high levels of 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine. 1982 Biochim. Biophys. Acta pmid:7126622
Vargaftig BB et al. Non-steroidal anti-inflammatory drugs if combined with anti-histamine and anti-serotonin agents interfere with the bronchial and platelet effects of "platelet-activating factor" (PAF-acether). 1982 Eur. J. Pharmacol. pmid:7128682
Namm DH et al. Species specificity of the platelet responses to 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine. 1982 Thromb. Res. pmid:7071810
Keraly CL and Benveniste J Specific desensitization of rabbit platelets by platelet-activating factor (PAF-acether) and derivatives. 1982 Br. J. Haematol. pmid:7082588
Wykle RL et al. Platelet activating factor (1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine). Activity of analogs lacking oxygen at the 2-position. 1982 FEBS Lett. pmid:7084476
Sánchez-Crespo M et al. Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: evidence for a platelet independent mechanism. 1982 Immunopharmacology pmid:7085259
Bach MK Mediators of anaphylaxis and inflammation. 1982 Annu. Rev. Microbiol. pmid:6128957
Mueller HW et al. Ether lipid content and fatty acid distribution in rabbit polymorphonuclear neutrophil phospholipids. 1982 Lipids pmid:7087685
Page CP et al. Platelet activation in asthma. 1982 N. Engl. J. Med. pmid:7088080
Chignard M et al. Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig. 1982 Eur. J. Pharmacol. pmid:6804248
Czarneztki BM Effect of platelet activating factor on leukocytes. II. Enhancement of eosinophil chemotactic factor and beta-glucuronidase release. 1982 Chem. Phys. Lipids pmid:6814773
Basran GS et al. Cromoglycate (DSCG) inhibits responses to platelet-activating factor (PAF-acether) in man: an alternative mode of action for DSCG in asthma? 1982 Eur. J. Pharmacol. pmid:6819153
Yasaka T et al. Monocyte aggregation and superoxide anion release in response to formyl-methionyl-leucyl-phenylalanine (FMLP) and platelet-activating factor (PAF). 1982 J. Immunol. pmid:6278021
Masugi F et al. Potent hypotensive activity of 1-O-hexadecyl-2-O-acetyl-SN-glycero-3-phosphocholine in spontaneously hypertensive rat. 1982 Biochem. Biophys. Res. Commun. pmid:7041899
Lapetina EG Platelet-activating factor stimulates the phosphatidylinositol cycle. Appearance of phosphatidic acid is associated with the release of serotonin in horse platelets. 1982 J. Biol. Chem. pmid:7045103
Caillard CG et al. Hypotensive activity of PAF-acether in rats. 1982 Agents Actions pmid:6299079
Smith RJ and Bowman BJ Stimulation of human neutrophil degranulation with 1-O-octadecyl-2-O-acetyl-SN-glyceryl-3-phosphorylcholine: modulation by inhibitors of arachidonic acid metabolism. 1982 Biochem. Biophys. Res. Commun. pmid:6803804
Larsen GL and Henson PM Mediators of inflammation. 1983 Annu. Rev. Immunol. pmid:6399978
Albert DH and Snyder F Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) from 1-alkyl-2-acyl-sn-glycero-3-phosphocholine by rat alveolar macrophages. Phospholipase A2 and acetyltransferase activities during phagocytosis and ionophore stimulation. 1983 J. Biol. Chem. pmid:6401298
König W et al. On the biological role of lipid chemotactic factors. 1983 Agents Actions Suppl. pmid:6404145
Ninio E et al. Biosynthesis of platelet-activating factor (PAF-acether). V. Enhancement of acetyltransferase activity in murine peritoneal cells by calcium ionophore A23187. 1983 Biochim. Biophys. Acta pmid:6405792
Alam I et al. Human and rabbit platelets form platelet-activating factor in response to calcium ionophore. 1983 Thromb. Res. pmid:6407140
Ostermann G et al. Studies on the stimulation of human blood platelets by semi-synthetic platelet-activating factor. 1983 Thromb. Res. pmid:6408754
Hopkins NK et al. Evidence for mediation of acetyl glyceryl ether phosphorylcholine stimulation of adenosine 3',5'-(cyclic)monophosphate levels in human polymorphonuclear leukocytes by leukotriene B4. 1983 Biochim. Biophys. Acta pmid:6313071
Mencia-Huerta JM et al. Antigen-initiated release of platelet-activating factor (PAF-acether) from mouse bone marrow-derived mast cells sensitized with monoclonal IgE. 1983 J. Immunol. pmid:6315819
Czarnetzki B Increased monocyte chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatoses. 1983 Clin. Exp. Immunol. pmid:6317241
Stimler NP and O'Flaherty JT Spasmogenic properties of platelet-activating factor: evidence for a direct mechanism in the contractile response of pulmonary tissues. 1983 Am. J. Pathol. pmid:6624879
Hartung HP Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7. 1983 FEBS Lett. pmid:6309563
Denjean A et al. Acute effects of intratracheal administration of platelet-activating factor in baboons. 1983 J Appl Physiol Respir Environ Exerc Physiol pmid:6629917
Camussi G et al. Biosynthesis and release of platelet-activating factor from human monocytes. 1983 Int. Arch. Allergy Appl. Immunol. pmid:6826235
Ogihara T et al. [Renomedullary hypotensive lipids and prostaglandins]. 1983 Horumon To Rinsho pmid:6368051
Tanaka S et al. Studies on the hypotensive effects of platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) in rats, guinea pigs, rabbits, and dogs. 1983 J. Pharmacobio-dyn. pmid:6668545
Saeki S et al. Hypotensive activity of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine in rats with various types of hypertension. 1983 Med J Osaka Univ pmid:6669136
Vargaftig BB Phospholipids, particularly platelet-activating factor (PAF-acether), in experimental bronchoconstriction. 1983 Agents Actions Suppl. pmid:6575594
Page CP et al. PAF-acether: a putative mediator of asthma and inflammation. 1983 Agents Actions Suppl. pmid:6575595
Valone FH and Goetzl EJ Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine. 1983 Immunology pmid:6848449
Chilton FH et al. Metabolic fate of platelet-activating factor in neutrophils. 1983 J. Biol. Chem. pmid:6853486
Stormorken H et al. A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). 1983 Thromb. Res. pmid:6857589
Kloprogge E et al. Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. 1983 Thromb. Res. pmid:6857605
Lecrubier C et al. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. 1983 Agents Actions pmid:6858789
Gonzalez-Crussi F and Hsueh W Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. 1983 Am. J. Pathol. pmid:6859226
Camussi G et al. Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor. 1983 Am. J. Pathol. pmid:6859232
Sánchez-Crespo M et al. Presence in normal human urine of a hypotensive and platelet-activating phospholipid. 1983 Am. J. Physiol. pmid:6859262
Hubbard JW et al. Antihypertensive effects of I-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine on plasma renin activity and catecholamine responses in spontaneously hypertensive rats. 1983 Life Sci. pmid:6337313
Acharya SB and MacIntyre DE Platelet products and vascular PGI2 production. 1983 Prostaglandins Leukot Med pmid:6338532
Camussi G et al. Effect of prostacyclin (PGI2) on immune-complex-induced neutropenia. 1983 Immunology pmid:6339375
Billah MM and Lapetina EG Platelet-activating factor stimulates metabolism of phosphoinositides in horse platelets: possible relationship to Ca2+ mobilization during stimulation. 1983 Proc. Natl. Acad. Sci. U.S.A. pmid:6341992
Lapetina EG and Siegel FL Shape change induced in human platelets by platelet-activating factor. Correlation with the formation of phosphatidic acid and phosphorylation of a 40,000-dalton protein. 1983 J. Biol. Chem. pmid:6345519
Camussi G et al. Inhibitory effect of prostacyclin (PGI2) on neutropenia induced by intravenous injection of platelet-activating-factor (PAF) in the rabbit. 1983 Prostaglandins pmid:6346397